1. Report Overview
1.1 Objectives of the Study
1.2 Introduction to CMO of Sterile Injectable Drugs Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Reports
1.10 About
2 Executive Summary
3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Growing Focus on Development to Treat Cancer
3.2.1.2 Rising Prevalence of Chronic Diseases
3.2.1.3 Rapid FDA Approvals of Sterile Injectable Drugs to Fuel Market Growth
3.2.1.4 As Manufacturers Invest in New Manufacturing Facilities, The Demand for Sterile Injectables is Expected to Rise
3.2.1.5 Increasing Demand for Biologicals is Expected to Drive the Demand
3.2.2 Market Restraining Factors
3.2.2.1 Growing Competition from Small Manufacturers
3.2.2.2 High Operational Costs
3.2.2.3 Inadequate Healthcare Infrastructure Across Developing Economies Challenging Market Growth
3.2.3 Market Opportunities
3.2.3.1 Prefilled Syringes to Offer Lucrative Growth Prospects
3.2.3.2 Growing Investments
3.2.3.3 Expanding Clinical Trial Opportunities in the Asia Pacific Region
3.2.4 Market Challenges
3.2.4.1 Disruption of Clinical Trials Due to Pandemic Breakout
3.3 COVID-19 Impact Analysis
3.4 Porter’s Five Forces Analysis
3.4.1 Supplier Power
3.4.2 Buyer Power
3.4.3 Competitive Rivalry
3.4.4 Threat from Substitutes
3.4.5 Threat of New Entrants
3.5 PEST Analysis
3.5.1 Political Factors Impacting CMO of Sterile Injectable Drugs Market
3.5.2 Economic Factors Impacting CMO of Sterile Injectable Drugs Market
3.5.3 Social Factors Impacting CMO of Sterile Injectable Drugs Market
3.5.4 Technological Factors Impacting CMO of Sterile Injectable Drugs Market
4 CMO of Sterile Injectable Drugs Market Analysis by Molecule Type
4.1 Key Findings
4.2 Molecule Type Segment: Market Attractiveness Index
4.3 CMO of Sterile Injectable Drugs Market Share by Molecule Type, 2022 & 2032
4.4 Small Molecule
4.5 Large Molecule
4.6 CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Molecule Type
5 CMO of Sterile Injectable Drugs Market Analysis by Type
5.1 Key Findings
5.2 Type Segment: Market Attractiveness Index
5.3 CMO of Sterile Injectable Drugs Market Share by Type, 2022 & 2032
5.4 Monoclonal Antibodies (mAbs)
5.5 Cytokines
5.6 Insulin
5.7 Peptide Hormones
5.8 Vaccines
5.9 Immunoglobulins
5.10 Blood Factor
5.11 Peptide Antibiotics
5.12 Others
5.13 CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Type
6 CMO of Sterile Injectable Drugs Market Analysis by Application
6.1 Key Findings
6.2 Application Segment: Market Attractiveness Index
6.3 CMO of Sterile Injectable Drugs Market Share by Application, 2022 & 2032
6.4 Cancer
6.5 Diabetes
6.6 Cardiovascular Diseases
6.7 CNS
6.8 Infectious
6.9 Others
6.10 CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Application
7 CMO of Sterile Injectable Drugs Market Analysis by Container Type
7.1 Key Findings
7.2 Container Type Segment: Market Attractiveness Index
7.3 CMO of Sterile Injectable Drugs Market Share by Container Type, 2022 & 2032
7.4 Bottles
7.5 Ampoules
7.6 Vials
7.7 Prefilled Syringes
7.8 Bags
7.9 CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Container Type
8 CMO of Sterile Injectable Drugs Market Analysis by Route of Administration
8.1 Key Findings
8.2 Route of Administration Segment: Market Attractiveness Index
8.3 CMO of Sterile Injectable Drugs Market Share by Route of Administration, 2022 & 2032
8.4 Subcutaneous
8.5 Intravenous
8.6 Intramuscular
8.7 Others
8.8 CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Route of Administration
9 CMO of Sterile Injectable Drugs Market Analysis by Service
9.1 Key Findings
9.2 Service Segment: Market Attractiveness Index
9.3 CMO of Sterile Injectable Drugs Market Share by Service, 2022 & 2032
9.4 Bioanalytical Testing
9.5 Method Development & Validation
9.6 Stability Testing
9.7 Others
9.8 CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Service
10 CMO of Sterile Injectable Drugs Market Analysis by Region
10.1 Key Findings
10.2 Regional Market Size Estimation and Forecast
11 North America CMO of Sterile Injectable Drugs Market Analysis
11.1 Key Findings
11.2 North America CMO of Sterile Injectable Drugs Market Attractiveness Index
11.3 North America CMO of Sterile Injectable Drugs Market by Country, 2022, 2027 & 2032 (US$ mn)
11.4 North America CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Country
11.5 North America CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Molecule Type
11.6 North America CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Type
11.7 North America CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Application
11.8 North America CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Container Type
11.9 North America CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Route of Administration
11.10 North America CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Service
11.11 U.S.
11.12 Canada
12 Europe CMO of Sterile Injectable Drugs Market Analysis
12.1 Key Findings
12.2 Europe CMO of Sterile Injectable Drugs Market Attractiveness Index
12.3 Europe CMO of Sterile Injectable Drugs Market by Country, 2022, 2027 & 2032 (US$ mn)
12.4 Europe CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Country
12.5 Europe CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Molecule Type
12.6 Europe CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Type
12.7 Europe CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Application
12.8 Europe CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Container Type
12.9 Europe CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Route of Administration
12.10 Europe CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Service
12.11 Germany
12.12 U.K.
12.13 France
12.14 Italy
12.15 Spain
12.16 Russia
12.17 Rest of Europe
13 Asia Pacific CMO of Sterile Injectable Drugs Market Analysis
13.1 Key Findings
13.2 Asia Pacific CMO of Sterile Injectable Drugs Market Attractiveness Index
13.3 Asia Pacific CMO of Sterile Injectable Drugs Market by Country, 2022, 2027 & 2032 (US$ mn)
13.4 Asia Pacific CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Country
13.5 Asia Pacific CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Molecule Type
13.6 Asia Pacific CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Type
13.7 Asia Pacific CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Application
13.8 Asia Pacific CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Container Type
13.9 Asia Pacific CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Route of Administration
13.10 Asia Pacific CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Service
13.11 China
13.12 Japan
13.13 India
13.14 Australia
13.15 South-East Asia
13.16 Rest of Asia Pacific
14 Latin America CMO of Sterile Injectable Drugs Market Analysis
14.1 Key Findings
14.2 Latin America CMO of Sterile Injectable Drugs Market Attractiveness Index
14.3 Latin America CMO of Sterile Injectable Drugs Market by Country, 2022, 2027 & 2032 (US$ mn)
14.4 Latin America CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Country
14.5 Latin America CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Molecule Type
14.6 Latin America CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Type
14.7 Latin America CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Application
14.8 Latin America CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Container Type
14.9 Latin America CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Route of Administration
14.10 Latin America CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Service
14.11 Brazil
14.12 Mexico
14.13 Rest of Latin America
15 Middle East & Africa CMO of Sterile Injectable Drugs Market Analysis
15.1 Key Findings
15.2 Middle East & Africa CMO of Sterile Injectable Drugs Market Attractiveness Index
15.3 Middle East & Africa CMO of Sterile Injectable Drugs Market by Country, 2022, 2027 & 2032 (US$ mn)
15.4 Middle East & Africa CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Country
15.5 Middle East & Africa CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Molecule Type
15.6 Middle East & Africa CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Type
15.7 Middle East & Africa CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Application
15.8 Middle East & Africa CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Container Type
15.9 Middle East & Africa CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Route of Administration
15.10 Middle East & Africa CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Service
15.11 GCC
15.12 South Africa
15.13 Rest of Middle East & Africa
16 Competitive Landscape
16.1 Company Share Analysis
16.2 Key Business Strategy Analysis
17 Company Profiles
17.1 Aenova Group
17.1.1 Company Snapshot
17.1.2 Company Overview
17.1.3 Product Benchmarking
17.1.4 Strategic Outlook
17.2 Almac Group
17.2.1 Company Snapshot
17.2.2 Company Overview
17.2.3 Product Benchmarking
17.2.4 Strategic Outlook
17.3 Baxter International Inc.
17.3.1 Company Snapshot
17.3.2 Company Overview
17.3.3 Financial Analysis
17.3.3.1 Net Revenue, 2017-2021
17.3.3.2 Regional Revenue/Market Shares, 2020
17.3.4 Product Benchmarking
17.3.5 Strategic Outlook
17.4 Boehringer Ingelheim International GmbH
17.4.1 Company Snapshot
17.4.2 Company Overview
17.4.3 Financial Analysis
17.4.3.1 Net Revenue, 2017-2021
17.4.3.2 Regional Revenue/Market Shares, 2021
17.4.3.3 Segmental Revenue/Market Shares, 2021
17.4.4 Product Benchmarking
17.5 Catalent, Inc.
17.5.1 Company Snapshot
17.5.2 Company Overview
17.5.3 Financial Analysis
17.5.3.1 Net Revenue, 2017-2021
17.5.3.2 Regional Revenue/Market Shares, 2021
17.5.3.3 Segmental Revenue/Market Shares, 2021
17.5.4 Product Benchmarking
17.5.5 Strategic Outlook
17.6 CordenPharma
17.6.1 Company Snapshot
17.6.2 Company Overview
17.6.3 Product Benchmarking
17.6.4 Strategic Outlook
17.7 Evonik Industries AG
17.7.1 Company Snapshot
17.7.2 Company Overview
17.7.3 Financial Analysis
17.7.3.1 Net Revenue, 2017-2021
17.7.3.2 Regional Revenue/Market Shares, 2021
17.7.3.3 Segmental Revenue/Market Shares, 2021
17.7.4 Product Benchmarking
17.7.5 Strategic Outlook
17.8 FAMAR Health Care Services
17.8.1 Company Snapshot
17.8.2 Company Overview
17.8.3 Product Benchmarking
17.8.4 Strategic Outlook
17.9 Fresenius Kabi Ag
17.9.1 Company Snapshot
17.9.2 Company Overview
17.9.3 Financial Analysis
17.9.3.1 Net Revenue, 2017-2021
17.9.3.2 Regional Revenue/Market Shares, 2021
17.9.3.3 Segmental Revenue/Market Shares, 2021
17.9.4 Product Benchmarking
17.9.5 Strategic Outlook
17.10 Grifols SA
17.10.1 Company Snapshot
17.10.2 Company Overview
17.10.3 Financial Analysis
17.10.3.1 Net Revenue, 2017-2021
17.10.3.2 Regional Revenue/Market Shares, 2021
17.10.3.3 Segmental Revenue/Market Shares, 2021
17.10.4 Product Benchmarking
17.10.5 Strategic Outlook
17.11 Hikma Pharmaceuticals PLC
17.11.1 Company Snapshot
17.11.2 Company Overview
17.11.3 Financial Analysis
17.11.3.1 Net Revenue, 2017-2021
17.11.3.2 Regional Revenue/Market Shares, 2021
17.11.3.3 Segmental Revenue/Market Shares, 2021
17.11.4 Product Benchmarking
17.11.5 Strategic Outlook
17.12 Jubilant Pharmova Limited
17.12.1 Company Snapshot
17.12.2 Company Overview
17.12.3 Financial Analysis
17.12.3.1 Net Revenue, 2017-2021
17.12.3.2 Regional Revenue/Market Shares, 2021
17.12.3.3 Segmental Revenue/Market Shares, 2021
17.12.4 Product Benchmarking
17.12.5 Strategic Outlook
17.13 Lonza
17.13.1 Company Snapshot
17.13.2 Company Overview
17.13.3 Financial Analysis
17.13.3.1 Net Revenue, 2017-2021
17.13.3.2 Regional Revenue/Market Shares, 2021
17.13.3.3 Segmental Revenue/Market Shares, 2021
17.13.4 Product Benchmarking
17.13.5 Strategic Outlook
17.14 Patheon, Inc. (Thermo Fischer)
17.14.1 Company Snapshot
17.14.2 Company Overview
17.14.3 Financial Analysis
17.14.3.1 Net Revenue, 2017-2021
17.14.3.2 Regional Revenue/Market Shares, 2021
17.14.3.3 Segmental Revenue/Market Shares, 2021
17.14.4 Product Benchmarking
17.14.5 Strategic Outlook
17.15 Pfizer CentreOne
17.15.1 Company Snapshot
17.15.2 Company Overview
17.15.3 Financial Analysis
17.15.3.1 Net Revenue, 2017-2021
17.15.3.2 Regional Revenue/Market Shares, 2021
17.15.3.3 Segmental Revenue/Market Shares, 2021
17.15.4 Product Benchmarking
17.15.5 Strategic Outlook
17.16 Recipharm AB
17.16.1 Company Snapshot
17.16.2 Company Overview
17.16.3 Product Benchmarking
17.16.4 Strategic Outlook
17.17 Siegfried Holding AG
17.17.1 Company Snapshot
17.17.2 Company Overview
17.17.3 Financial Analysis
17.17.3.1 Net Revenue, 2017-2021
17.17.3.2 Regional Revenue/Market Shares, 2021
17.17.3.3 Segmental Revenue/Market Shares, 2021
17.17.4 Product Benchmarking
17.17.5 Strategic Outlook
17.18 Nexus Pharmaceuticals, Inc.
17.18.1 Company Snapshot
17.18.2 Company Overview
17.18.3 Product Benchmarking
17.18.4 Strategic Outlook
17.19 Avara Pharmaceutical Services, Inc.
17.19.1 Company Snapshot
17.19.2 Company Overview
17.19.3 Product Benchmarking
17.20 Eli Lilly and Company
17.20.1 Company Snapshot
17.20.2 Company Overview
17.20.3 Financial Analysis
17.20.3.1 Net Revenue, 2017-2021
17.20.3.2 Regional Revenue/Market Shares, 2021
17.20.4 Product Benchmarking
17.20.5 Strategic Outlook
17.21 Adare Pharma Solutions
17.21.1 Company Snapshot
17.21.2 Company Overview
17.21.3 Product Benchmarking
17.21.4 Strategic Outlook
18 Conclusion and Recommendations
18.1 Concluding Remarks from
18.2 Recommendations for Market Players